Acambis retained at neutral by Merrill

Acambis plc kept a neutral rating from Merrill Lynch analyst Peter Welford. The company's 2005 results were generally in line with the analyst's forecasts, with revenues and gross margin exceeding Merrill's estimates. Acambis has not yet been awarded either of two potential smallpox vaccine U.S. government contracts, making some investors cautious in the near term. The company is confident it will receive a warm-base contract in 2006 for ACAM200 and Merrill forecasts $30 million is revenues in 2006 and beyond from such an award. Shares of the Cambridge, U.K., pharmaceutical company were down 9 cents, or 1.19%, at $7.45 on volume of 76,355 shares versus the three-month running average of 33,988 shares. (Nasdaq: ACAM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.